Statistical analyses:
In this study we evaluate genetic loads previously associated with known CMA comorbid diseases in a sample of former CMA cases and in a reference set. In these evaluations we assumed that inclusion of any of these comorbid diseases as covariate in our models would interfere with the factor of interest (genetic load per se) and thus redundant. Therefore, in none of our evaluations described below, were covariates included in the model. For each standardized PRS value (according the p-value threshold, PT), a parametric test (t-test) was performed to test for differences in the mean PRS between cases (former CMA patients) and the reference set. Significance levels of α ≤ 0.05 were assumed statistically significant. Binary logistic regression was performed to obtain odd ratios for all PRS PT thresholds. Odds ratios were presented as OR and the corresponding 95% confidence interval (C.I.). Association with prospective data of allergic traits with PRS were analyzed using an ANOVA test. Statistical analyses were performed in SPSS (IBM, v.24.0.0, Chicago, IL, USA).
Supplementary Discussion
Limitations and strengths of the study: A limitation of our study is the relative small sample size of our CMA cohort [10, 11] . In the present study we assumed nominal P-values as significant. One can argue that ignoring a multiple test penalty is inappropriate. However, our considerations of not applying such a penalty was based on the fact that most tests we performed were more or less not independent of each other, the latter is per the definition required for such adjustments. These dependencies are, though the exact shared genetic architecture is unknown, supported by accumulating evidence that showed that many disorders involving a hypersensitive immune system do share important immunological proteins or pathways [12] [13] [14] [15] . To this end, we considered our PRS tests, that were confirmed by follow-up data, as reliable and valid. Strict adjustment for multiple tests for these analyses would have resulted in too many false negative findings and misinterpretation of the true biological mechanism. However, as stated before, the results for which we were unable to validate by follow-up data, should be taken with caution. Another limiting factor was the fact that we were limited in the availability of sufficient DNA for genome-wide genotyping of the former 22 CMA patients, but not for the 307 subjects of the reference set. To overcome this issue of DNA availability, we performed genome-wide amplification only on the DNA of the former CMA patients. Although we found no evidence of considerable bias, e.g., disturbed genotypic heterozygosity or substantial numbers of deviations of the Hardy-Weinberg equilibrium, it is known that genome-wide amplification might induced some technical bias with respect to a limited number of SNPs. The variants that were affected were removed from analyses; therefore the risk that the genome-wide amplification per se affected our results was limited. Although both the reference set and former CMA patients were sampled in the Netherlands and thus the risk of population stratification is limited, we cannot exclude it. To our opinion the latter limitation was covered by the fact that we were able to validate our PRS studies on Asthma, AD and AR, using the available prospective data. For the others, i.e., ASD and IBD, we had no specific prospective information available and, thus, the prospective data was of lower meaningful value for these traits and results on these traits should be taken with a reasonable caution.
Supplementary Tables. Table S1 . Number of included SNPs (MAF > 0.01) in Polygenic Risk Score (PRS) analyses. Table S2 . Association analyses of asthma P < 0.001 and P < 1 Polygenic Risk Score (PRS) per follow-up symptom outcome. Y: Scoring on symptom= yes, N: Scoring on symptom= no. AST: Asthma; ASD Autism Spectrum Disorder. *ANOVA was performed to test for differences in means of the polygenic score between CMA patients scored for particular symptom or not. P < 0.05 was assumed statistically significant. Table S3 . Association analyses of autism P < 0.001 and P < 0.1 Polygenic Risk Score (PRS) per follow-up symptom outcome.
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